《大行報告》中金首予心瑋醫療-B(06609.HK)「跑贏行業」評級 目標價73元
中金公司發表研究報告,首次給予心瑋醫療(06609.HK)「跑贏行業」評級,目標價73元,指公司作為神經介入醫療器械的先行者,專注於提供一站式解決方案,在內地仍處於起步階段的神經介入手術市場,潛在增長迅速。
該行指,心瑋醫療擁有用於支架取栓術的完整產品套件產品,目標客群包括醫生及醫院,商業化能力通過驗證,看好其產品廣泛商業化及候選產品組合,預測2021至2023年每股虧損為4.34元、4.01元及1.1元人民幣,並於2024年扭虧,預期錄得每股盈利約1.88元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.